PapersFlow Research Brief
Neutropenia and Cancer Infections
Research Guide
What is Neutropenia and Cancer Infections?
Neutropenia and Cancer Infections refers to the management of febrile neutropenia and associated infections in cancer patients, particularly those with hematological malignancies undergoing chemotherapy, encompassing clinical practice guidelines, antimicrobial agents, granulocyte colony-stimulating factor use, risk assessment tools, prophylactic strategies, and their effects on morbidity and mortality.
This field addresses febrile neutropenia in cancer patients, with 35,036 papers documenting approaches like antimicrobial therapy and prophylaxis. Freifeld et al. (2011) updated guidelines for antimicrobial use in neutropenic cancer patients, expanding on prior IDSA recommendations from 1997 and 2002. Bodey et al. (1966) established quantitative links between leukocyte counts and infection rates in acute leukemia patients.
Topic Hierarchy
Research Sub-Topics
Antimicrobial Prophylaxis in Febrile Neutropenia
This sub-topic evaluates fluoroquinolone and antifungal prophylaxis regimens to prevent infections in neutropenic cancer patients undergoing chemotherapy. Researchers conduct randomized trials assessing efficacy, resistance emergence, and cost-effectiveness.
Risk Stratification Models for Neutropenic Fever
Studies develop and validate tools like MASCC index and clinical decision rules to classify patients for outpatient vs inpatient management of febrile neutropenia. Research incorporates biomarkers, comorbidities, and presentation features for personalized care.
Granulocyte Colony-Stimulating Factor in Neutropenia
This area investigates G-CSF (filgrastim, pegfilgrastim) for shortening neutropenia duration, reducing infection rates, and supporting dose-dense chemotherapy schedules. Meta-analyses evaluate therapeutic vs prophylactic use across solid tumors and leukemias.
Invasive Fungal Infections in Neutropenic Patients
Research focuses on aspergillosis, candidemia, and mucormycosis diagnosis, with biomarkers (galactomannan, beta-D-glucan), imaging, and PCR-based detection in hematological malignancy patients. Studies guide empiric antifungal therapy timing and choices.
Empiric Antibiotic Therapy for Febrile Neutropenia
This sub-topic examines monotherapy vs combination beta-lactam regimens, de-escalation strategies, and management of persistent fever in cancer patients. Guidelines evolve based on local resistance patterns and pharmacokinetic/pharmacodynamic data.
Why It Matters
Management of neutropenia-related infections directly influences survival in cancer patients receiving chemotherapy, as low leukocyte counts correlate with higher infection risks, with Bodey et al. (1966) reporting specific quantitative relationships in acute leukemia cases. Freifeld et al. (2011) provide updated IDSA guidelines recommending antimicrobial agents for febrile neutropenia, reducing morbidity and mortality in hematological malignancy patients. Hughes et al. (2002) outline prophylaxis strategies that prevent unexplained fever episodes, while Patterson et al. (2016) detail aspergillosis management, critical for immunocompromised individuals post-stem cell transplant, with adherence improving outcomes in clinical settings.
Reading Guide
Where to Start
"Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America" by Freifeld et al. (2011), as it provides the core updated framework for managing febrile neutropenia with antimicrobials, serving as an accessible entry to clinical guidelines.
Key Papers Explained
Freifeld et al. (2011) updates antimicrobial guidelines, building directly on Hughes et al. (2002), which revised earlier IDSA standards for febrile neutropenia. Bodey et al. (1966) supplies foundational quantitative data on leukocytes and infections, underpinning risk models in both. Patterson et al. (2016) extends fungal management specifics, connecting to Aşçıoğlu et al. (2002) consensus definitions for immunocompromised cases.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current guidelines emphasize tailored antimicrobial and antifungal prophylaxis per Freifeld et al. (2011) and Patterson et al. (2016), with focus on hematological malignancies and stem cell transplants. No recent preprints or news alter these standards. Frontiers involve integrating risk tools from Hughes et al. (2002) with modern chemotherapy regimens.
Papers at a Glance
Frequently Asked Questions
What are the IDSA guidelines for antimicrobial use in neutropenic cancer patients?
Freifeld et al. (2011) updated the 2010 IDSA guidelines for antimicrobial agents in neutropenic cancer patients with fever, building on 1997 and 2002 versions. These guidelines recommend initial empiric therapy and adjustments based on risk assessment. They serve as a reference for managing chemotherapy-induced neutropenia infections.
How do leukocyte counts relate to infection risk in leukemia patients?
Bodey et al. (1966) quantified relationships between circulating leukocytes and infection rates in acute leukemia patients. Lower counts directly increased infection incidence during chemotherapy. This foundational work informs modern risk stratification.
What defines opportunistic invasive fungal infections in cancer patients?
Aşçıoğlu et al. (2002) established an international consensus defining opportunistic invasive fungal infections in immunocompromised cancer and hematopoietic stem cell transplant patients. Criteria distinguish proven, probable, and possible cases. This standard aids diagnosis and treatment decisions.
What are the key updates in aspergillosis management guidelines?
Patterson et al. (2016) provided the 2016 IDSA update on diagnosing and managing aspergillosis in immunocompromised patients. Guidelines emphasize voluntary adherence tailored to individual cases. They address variations in neutropenic cancer patients.
How have antimicrobial guidelines evolved for neutropenic patients?
Hughes et al. (2002) issued IDSA guidelines updating 1990s recommendations for antimicrobial use in febrile neutropenic cancer patients. Freifeld et al. (2011) further refined these for modern chemotherapy regimens. Evolution focuses on prophylaxis and empiric therapy.
Open Research Questions
- ? What optimal risk assessment tools best predict infection outcomes in diverse cancer populations beyond acute leukemia?
- ? How can antimicrobial stewardship minimize resistance while effectively managing febrile neutropenia?
- ? Which prophylactic strategies most reduce aspergillosis incidence in hematopoietic stem cell transplant recipients?
- ? What refinements to granulocyte colony-stimulating factor dosing improve recovery in high-risk neutropenic patients?
Recent Trends
The field maintains steady documentation with 35,036 papers, though 5-year growth data is unavailable.
Core guidelines progressed from Hughes et al. to Freifeld et al. (2011), refining antimicrobial strategies for neutropenic cancer patients.
2002Patterson et al. represents the latest cited update on aspergillosis, with no new preprints or news in the last 12 months.
2016Research Neutropenia and Cancer Infections with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Neutropenia and Cancer Infections with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers